Novel Immunotherapeutic Approach in Gastric Cancer

Gastric cancer (GC) is suitable for immunotherapy because 80% of it display microsatellite and chromosomal instability, some mutations and DNA hypermethylation. Therefore, GC is more immunogenic. The immunotherapy with monoclonal antibodies, adoptive cell therapy and checkpoint inhibition are discus...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Gulubova M., Hadzhi M., Ignatova M., Chonov D., Balakan O., Aydan M., Ananiev J.
Formato:	article
Lenguaje:	EN
Publicado:	Sciendo 2020
Materias:	gastric cancer immunotherapy antibodies cell therapy Medicine R
Acceso en línea:	https://doaj.org/article/b5d19af524614ae6a6554ae15066ac52
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b5d19af524614ae6a6554ae15066ac52
record_format	dspace
spelling	oai:doaj.org-article:b5d19af524614ae6a6554ae15066ac522021-12-02T19:11:31ZNovel Immunotherapeutic Approach in Gastric Cancer0324-175010.2478/amb-2020-0024https://doaj.org/article/b5d19af524614ae6a6554ae15066ac522020-07-01T00:00:00Zhttps://doi.org/10.2478/amb-2020-0024https://doaj.org/toc/0324-1750Gastric cancer (GC) is suitable for immunotherapy because 80% of it display microsatellite and chromosomal instability, some mutations and DNA hypermethylation. Therefore, GC is more immunogenic. The immunotherapy with monoclonal antibodies, adoptive cell therapy and checkpoint inhibition are discussed. The commonly used monoclonal antibodies are Trastuzumab targeting HER2 and Bevacizumab suppressing VEGF and tumor angiogenesis. Treatment with tumor-specific T cells is called adoptive cell therapy. There is experience with the application of tumor infiltrating lymphocytes (TILs), cytotoxic T lymphocytes (CTLs) and cytokine-induced killer cells (CIK). This review discusses the therapy with innate immune cells with anti-tumor activity such as dendritic cells and NK cells. The checkpoint inhibition was also reviewed. In conclusion, it could be stated that the immunotherapy of GC has the potential to provide a more favorable outcome to patients with GC, but it also have some limitations which need to be considered.Gulubova M.Hadzhi M.Ignatova M.Chonov D.Balakan O.Aydan M.Ananiev J.Sciendoarticlegastric cancerimmunotherapyantibodiescell therapyMedicineRENActa Medica Bulgarica, Vol 47, Iss 2, Pp 47-54 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	gastric cancer immunotherapy antibodies cell therapy Medicine R
spellingShingle	gastric cancer immunotherapy antibodies cell therapy Medicine R Gulubova M. Hadzhi M. Ignatova M. Chonov D. Balakan O. Aydan M. Ananiev J. Novel Immunotherapeutic Approach in Gastric Cancer
description	Gastric cancer (GC) is suitable for immunotherapy because 80% of it display microsatellite and chromosomal instability, some mutations and DNA hypermethylation. Therefore, GC is more immunogenic. The immunotherapy with monoclonal antibodies, adoptive cell therapy and checkpoint inhibition are discussed. The commonly used monoclonal antibodies are Trastuzumab targeting HER2 and Bevacizumab suppressing VEGF and tumor angiogenesis. Treatment with tumor-specific T cells is called adoptive cell therapy. There is experience with the application of tumor infiltrating lymphocytes (TILs), cytotoxic T lymphocytes (CTLs) and cytokine-induced killer cells (CIK). This review discusses the therapy with innate immune cells with anti-tumor activity such as dendritic cells and NK cells. The checkpoint inhibition was also reviewed. In conclusion, it could be stated that the immunotherapy of GC has the potential to provide a more favorable outcome to patients with GC, but it also have some limitations which need to be considered.
format	article
author	Gulubova M. Hadzhi M. Ignatova M. Chonov D. Balakan O. Aydan M. Ananiev J.
author_facet	Gulubova M. Hadzhi M. Ignatova M. Chonov D. Balakan O. Aydan M. Ananiev J.
author_sort	Gulubova M.
title	Novel Immunotherapeutic Approach in Gastric Cancer
title_short	Novel Immunotherapeutic Approach in Gastric Cancer
title_full	Novel Immunotherapeutic Approach in Gastric Cancer
title_fullStr	Novel Immunotherapeutic Approach in Gastric Cancer
title_full_unstemmed	Novel Immunotherapeutic Approach in Gastric Cancer
title_sort	novel immunotherapeutic approach in gastric cancer
publisher	Sciendo
publishDate	2020
url	https://doaj.org/article/b5d19af524614ae6a6554ae15066ac52
work_keys_str_mv	AT gulubovam novelimmunotherapeuticapproachingastriccancer AT hadzhim novelimmunotherapeuticapproachingastriccancer AT ignatovam novelimmunotherapeuticapproachingastriccancer AT chonovd novelimmunotherapeuticapproachingastriccancer AT balakano novelimmunotherapeuticapproachingastriccancer AT aydanm novelimmunotherapeuticapproachingastriccancer AT ananievj novelimmunotherapeuticapproachingastriccancer
_version_	1718377111211737088

Novel Immunotherapeutic Approach in Gastric Cancer

Ejemplares similares